EcoDrugPlus

Tyrosine Kinase 2

Ensembl ID : ENSAPEG00000010745
Gene Symbol: TYK2
1 Cross references
196 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSAPEG00000019882
Gene Symbol: UTS2R
2 Cross references
92 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSAPEG00000007675
Gene Symbol: KRAS
1 Cross references
208 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSAPEG00000022944
Gene Symbol: AKT2
1 Cross references
199 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSAPEG00000012650
Gene Symbol: AKT2L
1 Cross references
185 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSAPEG00000003761
Gene Symbol: AKT3A
1 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSAPEG00000016091
Gene Symbol: RELA
1 Cross references
201 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSAPEG00000006990
Gene Symbol: VEGFAB
1 Cross references
198 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSAPEG00000005587
Gene Symbol: VDR
1 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex, Subunit 1

Ensembl ID : ENSAPEG00000010183
Gene Symbol: VKORC1
1 Cross references
191 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSAPEG00000009682
Gene Symbol: XDH
1 Cross references
210 Possible Orthologues:

Zgc:171772

Ensembl ID : ENSAPEG00000021880
Gene Symbol: ZGC:171772
1 Cross references
455 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).